BioCardia, Inc. 8-K

What Happened BioCardia, Inc. announced in a Form 8-K (filed June 12, 2026) that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after selling common stock through its At-The-Market (ATM) agreement with H.C. Wainwright & Co. The company reported selling a total of 4,004,330 shares from April 1 to June 5, 2026 (including 3,509,604 shares sold June 5), at an average price of about $1.27–$1.279 per share, generating net proceeds of $4.9 million. BioCardia received a Nasdaq notice on April 10, 2026 that its stockholders’ equity had fallen below the $2.5M minimum, submitted a compliance plan by May 25, 2026, and on June 9, 2026 Nasdaq granted an extension to October 7, 2026 to regain compliance.

Key Details

• Nasdaq notice received April 10, 2026 for stockholders’ equity below the $2.5M minimum (Rule 5550(b)(1)).
• Company submitted compliance plan May 25, 2026; Nasdaq extended compliance deadline to October 7, 2026 (notice dated June 9, 2026).
• Sold 4,004,330 shares under the ATM (April 1–June 5, 2026) at an average price ≈ $1.27, netting $4.9 million after fees.
• 3,509,604 of those shares were sold on June 5, 2026 at an average of $1.279 per share; company believes stockholders’ equity now exceeds $2.5M.

Why It Matters Regaining the $2.5M stockholders’ equity threshold avoids immediate Nasdaq delisting risk and allows the company to remain listed while it works to sustain compliance. The ATM sales provided near-term capital (net $4.9M) to improve the balance sheet, but Nasdaq will continue to monitor compliance and could delist the company if its next periodic report does not show continued compliance. Investors should note the company’s explicit caution that forward‑looking statements and risks are described in its filings (e.g., 2026 Form 10-K).